中国生物制药(1177HK):PDE3/4抑制剂II期临床数据亮眼 市场潜力巨大

招银国际
Oct 13

中国生物制药在欧洲呼吸学会2025 年会上公布了其PDE3/4 抑制剂TQC3721 的II 期临床结果,临床结果显示TQC3721 可快速改善患者肺功能和症状。240 例中重度中国慢阻肺(COPD)受试者在接受TQC3721 治疗4 周后,3mg/6mg 组受试者FEV1(第一秒用力呼气量)峰值较安慰剂组分别高100ml/147ml,在LAMA和LABA/LAMA 亚组中,6mg 组的FEV1 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10